Tumor-informed circulating tumor DNA (ctDNA) testing has not been evaluated in monitoring patients with primary urethral cancer (PUC) or penile squamous cell carcinoma (pSCC).
We investigated whether serial ctDNA monitoring correlated with clinical response in these rare genitourinary malignancies in the nonmetastatic, locally advanced setting.
